Regarding anti-IL-17 therapies, their mechanism of action in PRP likely involves the inhibition of IL-17-mediated keratinocyte proliferation and inflammatory pathways.1, 2 Ixekizumab, an anti-IL-17A antibody, is FDA-approved for the treatment of moderate to severe plaque psoriasis in children aged six years and older. The gene discussed is IL17A; the disease is psoriasis vulgaris.